|
12.0
|
https://www.ema.europa.eu/en/news/first-combined-covid-19-influenza-vaccine-people-50-years-older
|
N/A
|
4
|
|
12.0
|
https://www.ema.europa.eu/en/medicines/human/EPAR/mcombriax
|
N/A
|
4
|
|
6.0
|
https://www.ema.europa.eu/en/medicines/human/EPAR/supemtek
|
N/A
|
2
|
|
6.0
|
https://www.ema.europa.eu/en/medicines/human/EPAR/kyinsu
|
N/A
|
2
|
|
3.0
|
https://www.ema.europa.eu/en/medicines/human/EPAR/waskyra
|
N/A
|
1
|
|
3.0
|
https://www.ema.europa.eu/en/news/first-treatment-against-liver-scarring-caused-type-fatty-liver-disease
|
N/A
|
1
|
|
3.0
|
https://www.ema.europa.eu/en/medicines/human/EPAR/dawnzera
|
N/A
|
1
|
|
3.0
|
https://www.ema.europa.eu/en/news/new-injection-easier-prevention-hiv-infection-eu-worldwide
|
N/A
|
1
|
|
3.0
|
https://www.ema.europa.eu/en/medicines/human/EPAR/tryngolza
|
N/A
|
1
|
|
3.0
|
https://www.ema.europa.eu/en/medicines/human/EPAR/icotyde
|
N/A
|
1
|
|
3.0
|
https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-10-13-november-2025
|
N/A
|
1
|
|
3.0
|
https://www.ema.europa.eu/en/medicines/human/EPAR/boey
|
N/A
|
1
|
|
3.0
|
https://www.ema.europa.eu/en/medicines/human/EPAR/dazparda
|
N/A
|
1
|
|
3.0
|
https://www.ema.europa.eu/en/medicines/human/EPAR/waylivra
|
N/A
|
1
|
|
3.0
|
https://www.ema.europa.eu/en/medicines/human/EPAR/cenrifki
|
N/A
|
1
|
|
3.0
|
https://www.ema.europa.eu/en/documents/other/pandemrix-package-leaflet_en.pdf
|
N/A
|
1
|
|
3.0
|
https://www.ema.europa.eu/en/medicines/human/EPAR/onswik
|
N/A
|
1
|
|
3.0
|
https://www.ema.europa.eu/en/medicines/human/EPAR/itvisma
|
N/A
|
1
|
|
3.0
|
https://www.ema.europa.eu/en/medicines/human/EPAR/rezdiffra
|
N/A
|
1
|
|
3.0
|
https://www.ema.europa.eu/en/medicines/human/EPAR/acvybra
|
N/A
|
1
|
|
3.0
|
https://www.ema.europa.eu/en/news/prac-starts-safety-review-levamisole-medicine-used-treat-parasitic-worm-infections
|
N/A
|
1
|
|
3.0
|
https://www.ema.europa.eu/en/medicines/herbal/liquiritiae-radix#consultation-section
|
N/A
|
1
|
|
3.0
|
https://www.ema.europa.eu/en/medicines/human/EPAR/romvimza
|
N/A
|
1
|
|
3.0
|
https://www.ema.europa.eu/en/medicines/human/EPAR/isembyld
|
N/A
|
1
|
|
3.0
|
https://www.ema.europa.eu/en/medicines/human/EPAR/onerji
|
N/A
|
1
|
|
3.0
|
https://www.ema.europa.eu/en/medicines/human/EPAR/mynzepli
|
N/A
|
1
|
|
3.0
|
https://www.ema.europa.eu/en/medicines/human/EPAR/vislyfa
|
N/A
|
1
|
|
3.0
|
https://www.ema.europa.eu/en/medicines/human/EPAR/mnexspike
|
N/A
|
1
|
|
3.0
|
https://www.ema.europa.eu/en/medicines/human/EPAR/kygevvi
|
N/A
|
1
|
|
3.0
|
https://www.ema.europa.eu/en/medicines/human/EPAR/imaavy
|
N/A
|
1
|
|
3.0
|
https://www.ema.europa.eu/en/medicines/human/EPAR/ponlimsi
|
N/A
|
1
|
|
3.0
|
https://www.ema.europa.eu/en/medicines/human/EPAR/kayshild
|
N/A
|
1
|
|
3.0
|
https://www.ema.europa.eu/en/medicines/human/EPAR/bilprevda
|
N/A
|
1
|
|
3.0
|
https://www.ema.europa.eu/en/medicines/veterinary/EPAR/emepax
|
N/A
|
1
|
|
3.0
|
https://www.ema.europa.eu/en/medicines/human/EPAR/inluriyo
|
N/A
|
1
|
|
3.0
|
https://www.ema.europa.eu/en/medicines/human/EPAR/ondibta
|
N/A
|
1
|
|
3.0
|
https://www.ema.europa.eu/en/medicines/human/EPAR/galenvita
|
N/A
|
1
|
|
3.0
|
https://www.ema.europa.eu/en/medicines/human/EPAR/teizeild
|
N/A
|
1
|
|
3.0
|
https://www.ema.europa.eu/en/news/first-class-treatment-delay-onset-type-1-diabetes
|
N/A
|
1
|
|
3.0
|
https://www.ema.europa.eu/en/news/first-oral-glp-1-treatment-weight-management
|
N/A
|
1
|
|
3.0
|
https://www.ema.europa.eu/en/medicines/human/EPAR/afiveg
|
N/A
|
1
|
|
3.0
|
https://www.ema.europa.eu/en/medicines/human/EPAR/kefdensis
|
N/A
|
1
|
|
3.0
|
https://www.ema.europa.eu/en/news/etf-recommends-updating-covid-19-vaccines-target-new-lp81-variant
|
N/A
|
1
|
|
3.0
|
https://www.ema.europa.eu/en/medicines/human/referrals/monovalent-multivalent-measles-mumps-rubella-or-varicella-vaccines
|
N/A
|
1
|
|
3.0
|
https://www.ema.europa.eu/en/news/ema-starts-review-tavneos-medicine-rare-autoimmune-diseases-gpa-mpa
|
N/A
|
1
|
|
3.0
|
https://www.ema.europa.eu/en/medicines/human/referrals/tavneos
|
N/A
|
1
|
|
3.0
|
https://www.ema.europa.eu/en/medicines/human/EPAR/bildyos
|
N/A
|
1
|
|
3.0
|
https://www.ema.europa.eu/en/medicines/human/variation/wegovy
|
N/A
|
1
|
|
3.0
|
https://www.ema.europa.eu/en/medicines/human/EPAR/eiyzey
|
N/A
|
1
|
|
3.0
|
https://www.ema.europa.eu/en/news/first-oral-medicine-targeting-interleukin-23-receptor-recommended-plaque-psoriasis
|
N/A
|
1
|